Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

John Davis

Writer

London, U.K
A journalist and editor for more than 30 years, John has a broad interest in pharmaceuticals-related health care policy and breakthroughs in scientific and medical research.  He has degrees in biology and biochemical pharmacology.

Latest From John Davis

Pipeline Watch: Phase III Starts In Hypertension, Atopic Dermatitis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements

Pipeline Watch Approvals

ConserV Bioscience: Getting Ahead Of New COVID-19 Strains

The SEEK spin-out ConserV Bioscience is developing a broad-spectrum coronavirus vaccine, aiming to get ahead of the arrival of new strains of the virus.

Coronavirus COVID-19 Vaccines

Pipeline Watch: Phase III Starts In PAH, NSCLC And Seizure Disorders

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen

Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.

Deals Business Strategies

Denmark's IO Vaccine Biotech Attracts Investor Interest

Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.

ImmunoOncology Financing

COVID-19 Could Change Attitudes To Flu, Bolster Xofluza

Roche’s first-in-class one-dose antiviral Xofluza has been approved for marketing in the EU to treat influenza in patients aged 12 years or over, and for post-exposure prophylaxis.

Infectious Diseases Approvals
See All
UsernamePublicRestriction

Register